Business Context and Reporting Period
This Form 8-K is a current report filed by Predictive Oncology Inc. (not Axe Compute Inc.) on October 29, 2025. The filing addresses an update to the company's "at-the-market" (ATM) equity offering program under a registration statement on Form S-3.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, or debt levels. It focuses exclusively on equity offering limits:
- ATM Offering Limit: As of October 29, 2025, the company is eligible to sell common stock with an aggregate offering price of up to $18,330,000.
- Recent Sales Volume: During the 12 calendar months prior to and including the filing date, the company sold securities with an aggregate market value of approximately $2,417,337 under General Instruction I.B.6 of Form S-3.
- Public Float Threshold: The company notes that if its public float increases above $75.0 million, it will no longer be subject to the specific limits in General Instruction I.B.6 of Form S-3.
Material Changes
The primary material change is the amendment of the ATM Prospectus to update the maximum amount of shares eligible for sale. The filing clarifies that the $18,330,000 limit is subject to change based on fluctuations in the company's public float. If the public float increases, the company may sell additional amounts up to one-third of the public float, pending the filing of a new prospectus supplement.
Guidance, Outlook, and Risks
Management Commentary: The company intends to continue utilizing the ATM program with H.C. Wainwright & Co., LLC as the sales agent. Future sales are contingent on market conditions and the company's public float status.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful. The ability to sell additional shares is contingent on the public float increasing and the timely filing of subsequent prospectus supplements.
Investor Verification Checklist
- Verify the current public float of Predictive Oncology Inc. to determine if the $18,330,000 ATM limit remains accurate or if it has been adjusted.
- Confirm the total number of shares sold under the ATM program since the last reporting period to assess dilution impact.
- Review the full ATM Sales Agreement with H.C. Wainwright & Co., LLC for commission rates and termination clauses.
- Check for any subsequent prospectus supplements filed after October 29, 2025, that may have increased the offering cap.